32245-87-7

Basic information

• Product Name: Piperidine, 1-acetyl-4-phenyl-
• CAS NO: 32245-87-7
• Molecular Formula: C13H17NO
• Molecular Weight: 203.284
• Mol File: 32245-87-7.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: Piperidine, 1-acetyl-4-phenyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Piperidine, 1-acetyl-4-phenyl-(32245-87-7)
• EPA Substance Registry System: Piperidine, 1-acetyl-4-phenyl-(32245-87-7)

Safety Data

• Hazardous Substances Data: 32245-87-7(Hazardous Substances Data)

Upstream product

• 771-99-3 4-phenylpiperidine 
• 75-36-5 acetyl chloride 
• 108-24-7 acetic anhydride 
• 110-86-1 pyridine 
• 100-59-4 phenylmagnesium chloride 

Downstream Products

• 112069-10-0 4-<4-(1-acetyl-4-piperidinyl)phenyl>-4-oxobutanoic acid 
• 120447-44-1 N-acetyl-4-(2,4-dinitrophenyl)piperidine 
• 149353-84-4 4-(4-carboxyphenyl)-piperidine-hydrochloride 
• 1622204-21-0 (5-({2-[({4-[1-(2-hydroxyethyl)piperidin-4-yl]phenyl}carbonyl)amino]pyridin-4-yl}oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide) 
• 1622204-19-6 6-(2-methoxyethoxy)-N-methyl-5-{[2-({[4-(piperidin-4-yl)phenyl]carbonyl}amino)pyridin-4-yl]oxy}-1H-indole-1-carboxamide 
• 149353-75-3 4-(1-(tert-butoxycarbonyl)piperidin-4-yl)benzoic acid 
• 196204-01-0 4-(piperidin-4-yl)-benzoic acid 
• 120447-45-2 4-(2,4-Dinitro-phenyl)-piperidine 

Relevant articles and documents

Design and synthesis of sulfonamidophenylethylureas as novel cardiac myosin activator

To optimize the lead urea scaffold 1 and 2 as selective cardiac myosin ATPase activator, a series of urea derivatives have been synthesized to explore its structure activity relationship. Among them N,N-dimethyl-4-(2-(3-(3-phenylpropyl)ureido)ethyl)benzenesulfonamide (13, CMA = 91.6%, FS = 17.62%; EF = 11.55%), N,N-dimethyl-4-(2-(1-methyl-3-(3-phenylpropyl)ureido)ethyl)benzene sulfonamide (40, CMA = 52.3%, FS = 38.96%; EF = 24.19%) and N,N-dimethyl-4-(2-(3-methyl-3-(3-phenylpropyl)ureido)ethyl)benzenesulfonamide (41, CMA = 47.6%, FS = 23.19%; EF = 15.47%) proved to be efficient to activate the cardiac myosin in vitro and in vivo. Further the % change in ventricular cell contractility at 5 μM of 13 (47.9 ± 3.2), 40 (45.5 ± 2.4) and 41 (63.5 ± 2.2) showed positive inotropic effect in isolated rat ventricular myocytes. The potent compounds 13, 40, 41 were highly selective for cardiac myosin over skeletal and smooth muscle myosin, thus proving them these new urea derivatives is a novel scaffold for discovery of cardiac myosin activators for the treatment of systolic heart failure.

Compounds with cardiac myosin activating function and pharmaceutical composition containing the same for treating or preventing heart failure

The present invention relates to a compound having a cardiotonic activating function and a pharmaceutical composition containing the same. The composition comprising the compound according to the present invention is effective in preventing or treating heart failure. In addition, the compound is represented by chemical formula 2 or is pharmaceutically acceptable salt thereof.COPYRIGHT KIPO 2016

MONOCYCLIC PYRIDINE DERIVATIVE

The present invention provides a novel compound having FGFR inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same. Specifically, the present invention provides a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein n represents 0 to 2; A represents an arylene group or a heteroarylene group; G represents a single bond, an oxygen atom or —CH2—; E represents a nitrogen-containing non-aromatic heterocycle; R1 represents an alkoxy group or the like; R2 represents a hydrogen atom or the like; and R3 represents a hydrogen atom, an alkyl group, an alkoxy group or the like, with the proviso that when E represents an azetidine ring and R2 or R3 is present on a nitrogen atom on the azetidine ring, the R2 or R3 does not represent a hydrogen atom.